Fenofibrate-UDCA Combination Therapy Safe and Effective for Primary Biliary Cholangitis

New research by Cleveland Clinic physicians, presented at the 2026 Digestive Disease Week Conference, confirms that a combination therapy of ursodeoxycholic acid (UDCA) and fenofibrate is safe and effective for patients with primary biliary cholangitis (PBC) who do not respond to UDCA alone. This large, retrospective study found improved outcomes after one and five years of treatment, with no increased cardiovascular or liver risks. This provides evidence for an approach hepatologists have prescribed off-label for years.

Context

Primary biliary cholangitis is a chronic liver disease that can lead to serious complications. UDCA has been the standard treatment, but not all patients respond adequately. The combination of UDCA and fenofibrate has been used off-label, and this study provides robust evidence supporting its safety and efficacy.

Why it matters

The findings from this study are significant for patients with primary biliary cholangitis (PBC) who do not respond to standard treatment with ursodeoxycholic acid (UDCA). It offers a new, effective treatment option that could improve patient outcomes. This research may influence clinical practices and guidelines for managing PBC, potentially benefiting a large number of patients.

Implications

The study's results could lead to improved management strategies for PBC, enhancing the quality of life for patients. Insurance coverage policies may change to include this combination therapy, making it more accessible. Additionally, this research may prompt further investigations into other off-label treatments for liver diseases.

What to watch

Healthcare providers may begin to adopt this combination therapy more widely in their treatment plans for PBC. Future studies could explore the long-term effects and optimal dosing of this therapy. Monitoring guidelines and recommendations from hepatology associations may also evolve in response to these findings.